Literature DB >> 14664473

Bone status in multiple sclerosis: beyond corticosteroids.

Sansin Tüzün1, Ayşe Altintaş, Ilhan Karacan, Saliha Tangürek, Sebahattin Saip, Aksel Siva.   

Abstract

The aim of this study was to determine the possible factors affecting bone mineral density (BMD) in multiple sclerosis (MS). In this cross-sectional study, 65 clinically definite MS patients and 72 comparable controls were prospectively evaluated. To assess bone mineral metabolism in MS, the BMD of the lumbar spine and hip (femoral neck, trochanter and total) was measured by dual-energy X-ray absorptiometry, and serum vitamin D and parathyroid hormone levels and biochemical markers of bone turnover were also evaluated. MS patients had significantly lower BMD values than the control group at all measurement sites. There was a significant correlation between the disease duration and BMD values at the trochanter in women with MS. A correlation between femoral BMD values and functional status in women was also detected. There was no relationship between bone biochemical markers and BMD, except a negative correlation between bone alkaline phosphatase and trochanter BMD. Both disability and disease duration have an influence on BMD of the MS patients, whereas no significant correlation between glucocorticoid use and BMD was observed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14664473     DOI: 10.1191/1352458503ms966oa

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  20 in total

1.  Asymmetrical hip bone density in multiple sclerosis.

Authors:  Rebecca D Larson; Lesley J White
Journal:  Int J MS Care       Date:  2011

2.  Bone turnover and metabolism in patients with early multiple sclerosis and prevalent bone mass deficit: a population-based case-control study.

Authors:  Stine Marit Moen; Elisabeth Gulowsen Celius; Leiv Sandvik; Magritt Brustad; Lars Nordsletten; Erik Fink Eriksen; Trygve Holmøy
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

Review 3.  Bone health in multiple sclerosis.

Authors:  J C Gibson; G D Summers
Journal:  Osteoporos Int       Date:  2011-05-21       Impact factor: 4.507

4.  A simple score for estimating the long-term risk of fracture in patients with multiple sclerosis.

Authors:  Marloes T Bazelier; Tjeerd-Pieter van Staa; Bernard M J Uitdehaag; Cyrus Cooper; Hubert G M Leufkens; Peter Vestergaard; Joan Bentzen; Frank de Vries
Journal:  Neurology       Date:  2012-08-15       Impact factor: 9.910

5.  Bone mineral density in ambulatory patients with multiple sclerosis.

Authors:  Chrissa Sioka; Stylianos Papakonstantinou; Andreas Fotopoulos; Yiannis Alamanos; Athanasia Georgiou; Sofia Tsouli; Sygliti-Henrietta Pelidou; Athanassios P Kyritsis; John Kalef-Ezra
Journal:  Neurol Sci       Date:  2011-05-18       Impact factor: 3.307

Review 6.  Risk Factors, Epidemiology and Treatment Strategies for Metabolic Bone Disease in Patients with Neurological Disease.

Authors:  S Binks; R Dobson
Journal:  Curr Osteoporos Rep       Date:  2016-10       Impact factor: 5.096

Review 7.  Osteoporosis and multiple sclerosis: risk factors, pathophysiology, and therapeutic interventions.

Authors:  Sahil Gupta; Irfan Ahsan; Naeem Mahfooz; Noureldin Abdelhamid; Murali Ramanathan; Bianca Weinstock-Guttman
Journal:  CNS Drugs       Date:  2014-08       Impact factor: 5.749

8.  Body composition in multiple sclerosis.

Authors:  Y Dionyssiotis
Journal:  Hippokratia       Date:  2013-01       Impact factor: 0.471

9.  Predictors and prevalence of low bone mineral density in fully ambulatory persons with multiple sclerosis.

Authors:  Linn Hofsøy Steffensen; Svein Ivar Mellgren; Margitta T Kampman
Journal:  J Neurol       Date:  2009-10-01       Impact factor: 4.849

10.  Risk of fractures in patients with multiple sclerosis: a population-based cohort study.

Authors:  M T Bazelier; T-P van Staa; B M J Uitdehaag; C Cooper; H G M Leufkens; P Vestergaard; R M C Herings; F de Vries
Journal:  Neurology       Date:  2012-05-16       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.